Medtronic PLC (MDT) is Reiterated by Needham to Buy, Lowers Price Target to $ 84

Medtronic PLC (MDT) was Reiterated by Needham to “Buy” while Lowering the Price Target of the company shares to $ 84 from a previous price target of $95 . Needham advised their investors in a research report released on Nov 23, 2016.

Many Wall Street Analysts have commented on Medtronic PLC. Company shares were Reiterated by Needham on Aug 26, 2016 to “Buy”, Firm has raised the Price Target to $ 95 from a previous price target of $93 .

On the company’s financial health, Medtronic PLC reported $1.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Nov 22, 2016. Analyst had a consensus of $1.11. The company had revenue of $7345.00 million for the quarter, compared to analysts expectations of $7459.64 million. The company’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 EPS.

Medtronic PLC closed down -0.87 points or -1.06% at $80.93 with 46,74,186 shares getting traded on Monday. Post opening the session at $81.71, the shares hit an intraday low of $80.82 and an intraday high of $81.91 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Sep 28, 2016, Richard Kuntz (SrVP & Chief Scien, Clin, Reg) sold 42,340 shares at $86.68 per share price. According to the SEC, on Sep 19, 2016, Kendall J Powell (director) sold 7,907 shares at $85.44 per share price. On Sep 19, 2016, Omar Ishrak (Chairman & CEO) sold 61,925 shares at $84.93 per share price, according to the Form-4 filing with the securities and exchange commission.

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops manufactures and markets its medical devices and technologies to hospitals physicians clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group Minimally Invasive Technologies Group Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine Neuromodulation Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic Inc. is a subsidiary of the Company.

Medtronic PLC

Leave a Reply

Medtronic PLC - Is it time to Sell?

Top Brokerage Firms are advising their investors on Medtronic PLC. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.